Novartis has been actively engaging in major biotech deals as evident by their $2 billion purchase of immunology biotech Excellergy and considering their recent mixed share price performance.
Morgan Stanley forecasts a strong price appreciation for Novartis stock, which has experienced a recent fall following the $2B acquisition of Excellergy. There is a general curiosity about the fair pricing of Novartis given the recent share volatility and solid earnings growth. Novartis has made a large bet on allergy drug pipeline sinking $2 billion. Despite shares trading at an all-time high of $146.4, questions abound if there's still room for growth in Novartis shares following multi-year rallies. Many are optimistic especially with new stock purchases by financial institutions such as
JPMorgan Chase & Co and
CIBC Private Wealth Group LLC. Notably,
Jim Cramer has shown optimism about Novartis’ cancer drug, and reports suggest a possible $1.7 billion development deal for Novartis. The
CEO of Novartis has indicated readiness for big M&A deals, while shares of Novartis have hit another high at $167.87. Novartis has also shown strong performance in 2025, leading to a 30% increase in the CEO's pay. However, with increasing investments and growth in their pipeline, some analysts like
Goldman Sachs believe the stock is overvalued. Looking ahead, Novartis has increased its full-year guidance to reflect recent acquisitions and portfolio growth.
Novartis Stocks News Analytics from Fri, 12 Sep 2025 07:00:00 GMT to Sat, 28 Mar 2026 09:48:00 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -1
